FY2029 Earnings Estimate for NMRA Issued By William Blair

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – William Blair issued their FY2029 earnings per share estimates for shares of Neumora Therapeutics in a report issued on Thursday, January 2nd. William Blair analyst M. Minter anticipates that the company will earn $1.47 per share for the year. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period in the prior year, the firm earned ($1.14) earnings per share.

A number of other analysts also recently issued reports on NMRA. Royal Bank of Canada downgraded shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $29.00 to $4.00 in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Neumora Therapeutics in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a report on Thursday. Finally, JPMorgan Chase & Co. cut Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.40.

Neumora Therapeutics Price Performance

Shares of Neumora Therapeutics stock opened at $2.17 on Monday. The company has a 50 day simple moving average of $10.47 and a two-hundred day simple moving average of $11.51. The firm has a market cap of $350.59 million, a PE ratio of -1.16 and a beta of 3.34. Neumora Therapeutics has a 1 year low of $1.83 and a 1 year high of $21.00.

Hedge Funds Weigh In On Neumora Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Amalgamated Bank lifted its holdings in Neumora Therapeutics by 472.8% in the 2nd quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after buying an additional 2,402 shares during the period. Quarry LP purchased a new stake in shares of Neumora Therapeutics in the 2nd quarter worth about $98,000. SkyOak Wealth LLC purchased a new position in shares of Neumora Therapeutics during the second quarter valued at about $147,000. Principal Financial Group Inc. bought a new position in Neumora Therapeutics in the second quarter worth about $166,000. Finally, Intech Investment Management LLC purchased a new stake in Neumora Therapeutics in the third quarter worth about $175,000. 47.65% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Matthew K. Fust sold 14,049 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the sale, the director now directly owns 20,100 shares in the company, valued at $342,303. This represents a 41.14 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Robert A. Lenz sold 5,563 shares of the stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the sale, the insider now directly owns 322,966 shares of the company’s stock, valued at $4,847,719.66. The trade was a 1.69 % decrease in their position. The disclosure for this sale can be found here. 26.40% of the stock is currently owned by insiders.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.